JP2008512479A5 - - Google Patents

Download PDF

Info

Publication number
JP2008512479A5
JP2008512479A5 JP2007531333A JP2007531333A JP2008512479A5 JP 2008512479 A5 JP2008512479 A5 JP 2008512479A5 JP 2007531333 A JP2007531333 A JP 2007531333A JP 2007531333 A JP2007531333 A JP 2007531333A JP 2008512479 A5 JP2008512479 A5 JP 2008512479A5
Authority
JP
Japan
Prior art keywords
antibody
medicament according
death receptor
receptor
agonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007531333A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008512479A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2005/032015 external-priority patent/WO2006029275A2/en
Publication of JP2008512479A publication Critical patent/JP2008512479A/ja
Publication of JP2008512479A5 publication Critical patent/JP2008512479A5/ja
Pending legal-status Critical Current

Links

JP2007531333A 2004-09-08 2005-09-07 デスレセプターリガンド及びcd20抗体の使用方法 Pending JP2008512479A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US60783404P 2004-09-08 2004-09-08
US66655005P 2005-03-30 2005-03-30
PCT/US2005/032015 WO2006029275A2 (en) 2004-09-08 2005-09-07 Methods of using death receptor ligands and cd20 antibodies

Publications (2)

Publication Number Publication Date
JP2008512479A JP2008512479A (ja) 2008-04-24
JP2008512479A5 true JP2008512479A5 (cg-RX-API-DMAC7.html) 2008-10-23

Family

ID=35788041

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007531333A Pending JP2008512479A (ja) 2004-09-08 2005-09-07 デスレセプターリガンド及びcd20抗体の使用方法

Country Status (13)

Country Link
US (2) US20090175854A1 (cg-RX-API-DMAC7.html)
EP (1) EP1802660A2 (cg-RX-API-DMAC7.html)
JP (1) JP2008512479A (cg-RX-API-DMAC7.html)
KR (1) KR20070050951A (cg-RX-API-DMAC7.html)
CN (1) CN101048428A (cg-RX-API-DMAC7.html)
AU (1) AU2005282397A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0515604A (cg-RX-API-DMAC7.html)
CA (1) CA2577828A1 (cg-RX-API-DMAC7.html)
IL (1) IL181315A0 (cg-RX-API-DMAC7.html)
NO (1) NO20071789L (cg-RX-API-DMAC7.html)
NZ (1) NZ553171A (cg-RX-API-DMAC7.html)
RU (1) RU2007112952A (cg-RX-API-DMAC7.html)
WO (1) WO2006029275A2 (cg-RX-API-DMAC7.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7361341B2 (en) 2001-05-25 2008-04-22 Human Genome Sciences, Inc. Methods of treating cancer using antibodies that immunospecifically bind to trail receptors
US7348003B2 (en) 2001-05-25 2008-03-25 Human Genome Sciences, Inc. Methods of treating cancer using antibodies that immunospecifically bind to TRAIL receptors
HUE038955T2 (hu) * 2003-11-05 2018-12-28 Roche Glycart Ag Antigén-kötõ molekulák fokozott Fc receptor-kötõ affinitással és effektor funkcióval
BRPI0509201A (pt) 2004-03-23 2007-08-28 Biogen Idec Inc agentes de acoplamento de receptor e usos terapêuticos destes
WO2008066854A2 (en) * 2006-11-28 2008-06-05 Novartis Ag Methods and compositions for inducing apoptosis in cancer cells
JP5624471B2 (ja) * 2007-09-24 2014-11-12 バーイラン ユニバーシティー 磁性金属酸化物で被覆されたポリマー性ナノ粒子及びその使用
AR073295A1 (es) 2008-09-16 2010-10-28 Genentech Inc Metodos para tratar la esclerosis multiple progresiva. articulo de fabricacion.
AR078161A1 (es) * 2009-09-11 2011-10-19 Hoffmann La Roche Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
JP5950824B2 (ja) 2009-12-07 2016-07-13 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 抗腫瘍抗体療法を増強するための方法
PH12012501157A1 (en) 2009-12-22 2012-10-29 Roche Glycart Ag Anti-her3 antibodies and uses thereof
AR094403A1 (es) 2013-01-11 2015-07-29 Hoffmann La Roche Terapia de combinación de anticuerpos anti-her3
CN107250161A (zh) 2015-01-26 2017-10-13 宏观基因有限公司 包含dr5‑结合结构域的多价分子
CA3045944A1 (en) 2016-12-07 2018-06-14 Progenity, Inc. Gastrointestinal tract detection methods, devices and systems
CA3054632A1 (en) 2017-03-30 2018-10-04 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
US20230041197A1 (en) 2018-06-20 2023-02-09 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
US12227565B2 (en) 2018-06-20 2025-02-18 Biora Therapeutics, Inc. Method of formulating a pharmaceutical composition comprising administering an immune modulator to the small intestine
CN113348011B (zh) 2018-11-19 2023-04-18 比奥拉治疗股份有限公司 用生物治疗剂治疗疾病的方法和装置
CN121197633A (zh) 2019-12-13 2025-12-26 比特比德科有限责任公司 用于将治疗剂递送至胃肠道的可摄取装置
WO2023091887A1 (en) 2021-11-16 2023-05-25 Genentech, Inc. Methods and compositions for treating systemic lupus erythematosus (sle) with mosunetuzumab

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85035A0 (en) * 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5736137A (en) * 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
AU704440B2 (en) * 1994-02-04 1999-04-22 Bio Merieux MSRV1 virus and MSRV2 pathogenic and/or infectious agent associated with multiple sclerosis, nucleic acid components and applications of same
CA2225378C (en) * 1995-06-29 2012-04-17 Immunex Corporation Cytokine that induces apoptosis
US6998116B1 (en) * 1996-01-09 2006-02-14 Genentech, Inc. Apo-2 ligand
US6030945A (en) * 1996-01-09 2000-02-29 Genentech, Inc. Apo-2 ligand
ATE362982T1 (de) * 1997-01-28 2007-06-15 Human Genome Sciences Inc ßDEATH-DOMAINß-ENTHALTENDER REZEPTOR 4 (DR4), EIN MITGLIED DER TNF-REZEPTOR SUPERFAMILIE, WELCHER AN TRAIL (APO-2L) BINDET
US6433147B1 (en) * 1997-01-28 2002-08-13 Human Genome Sciences, Inc. Death domain containing receptor-4
US6072047A (en) * 1997-02-13 2000-06-06 Immunex Corporation Receptor that binds trail
US20020160446A1 (en) * 2000-11-14 2002-10-31 Holtzman Douglas A. Novel genes encoding proteins having prognostic diagnostic preventive therapeutic and other uses
US20010010924A1 (en) * 1997-03-14 2001-08-02 Keith Charles Deen Tumor necrosis factor related receptor, tr6 polynecleotides
US6313269B1 (en) * 1997-03-14 2001-11-06 Smithkline Beecham Corporation Tumor necrosis factor related receptor, TR6
NZ508381A (en) * 1997-03-17 2002-09-27 Human Genome Sciences Inc Antibodies, antagonists and agonists of the death domain containing receptor 5 (DR5)
US6872568B1 (en) * 1997-03-17 2005-03-29 Human Genome Sciences, Inc. Death domain containing receptor 5 antibodies
WO1998046643A1 (en) * 1997-04-16 1998-10-22 Millennium Biotherapeutics, Inc. TUMOR NECROSIS FACTOR RECEPTOR RELATED PROTEINS TANGO-63d AND TANGO-63e
US6342369B1 (en) * 1997-05-15 2002-01-29 Genentech, Inc. Apo-2-receptor
PT1053256E (pt) * 1998-01-26 2011-09-28 Genentech Inc Anticorpos para o receptor de morte 4 (dr4) e utilizações destes
US6252050B1 (en) * 1998-06-12 2001-06-26 Genentech, Inc. Method for making monoclonal antibodies and cross-reactive antibodies obtainable by the method
CA2439735A1 (en) * 2001-03-14 2002-09-19 Genentech, Inc. Igf antagonist peptides
EP1506285B1 (en) * 2001-11-01 2010-12-08 Uab Research Foundation Combinations of anti-dr5 antibodies and anti-dr4 antibodies and other therapeutic agents

Similar Documents

Publication Publication Date Title
Ishii et al. Defucosylated humanized anti-CCR4 monoclonal antibody KW-0761 as a novel immunotherapeutic agent for adult T-cell leukemia/lymphoma
JP2008513367A5 (cg-RX-API-DMAC7.html)
CN107660151B (zh) 抗-cd19抗体和布鲁顿酪氨酸激酶抑制剂的组合及其用途
Yano et al. Defucosylated anti–CC chemokine receptor 4 monoclonal antibody combined with immunomodulatory cytokines: a novel immunotherapy for aggressive/refractory mycosis fungoides and Sézary syndrome
Makita et al. Mogamulizumab for the treatment of T-cell lymphoma
Beckwith et al. The CD37-targeted antibody–drug conjugate IMGN529 is highly active against human CLL and in a novel CD37 transgenic murine leukemia model
JP2014501729A5 (cg-RX-API-DMAC7.html)
AU7626000A (en) Treatment of patients having non-hodgkins lymphoma with bone marrow involvement with anti-cd20 antibodies
WO2005044854A3 (en) Antagonist anti-cd40 monoclonal antibodies and methods for their use
JP2008513354A5 (cg-RX-API-DMAC7.html)
RS62260B1 (sr) Kombinacije i njihova upotreba
RU2007112952A (ru) Способы применения лигандов рецепторов смерти и cd20-антител
US20230014026A1 (en) Anti-Tumor Combination Therapy comprising Anti-CD19 Antibody and Polypeptides Blocking the SIRPalpha-CD47 Innate Immune Checkpoint
CN101678101B (zh) 可用于诊断和治疗b细胞慢性淋巴细胞白血病的能够在肿瘤细胞中诱导凋亡的药物组合物
Georgakopoulou et al. Biological agents: what they are, how they affect oral health and how they can modulate oral healthcare
Ishida et al. Antibody therapy for Adult T-cell leukemia–lymphoma
Shalabi et al. Immune evasion and current immunotherapy strategies in mycosis fungoides (MF) and Sézary syndrome (SS)
JP2006528627A5 (cg-RX-API-DMAC7.html)
Xiao et al. Targeting the CD47-SIRPα axis: Present therapies and the future for cutaneous T-cell lymphoma
US20250074981A1 (en) Combination therapy with dexamethasone and tumor-specific t cell engaging multi-specific antibodies for treating cancer
CN113613678A (zh) 使用抗cd30抗体药物缀合物疗法治疗外周t细胞淋巴瘤的方法
JP2021517144A (ja) Cd47遮断療法およびcd38抗体の組み合わせ
Stanley et al. Critical roles for LIGHT and its receptors in generating T cell-mediated immunity during Leishmania donovani infection
Bhandari et al. Novel applications of Rituximab in dermatological disorders
Tay et al. Novel agents for B-cell non-Hodgkin lymphoma: science and the promise